Comparison with the literature
Although this study marks the first comprehensive economic evaluation
for this intervention, the findings of it align with those reported in
an abstract by Owens19. This US study also found
co-amoxiclav prophylaxis to be a dominant strategy – even following
sensitivity analysis19. Although there are differences
in demographics and cost of treatments between the two countries, the
alignment of findings further reiterates the prospective role of
co-amoxiclav in the prevention of maternal infection.